Patents by Inventor Philip J. Barr

Philip J. Barr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10837031
    Abstract: The present invention relates generally to production methods, enzymes and recombinant yeast strains for the biosynthesis of clinically important prenylated polyketides of the cannabinoid family. Using readily available starting materials, heterologous enzymes are used to direct cannabinoid biosynthesis in yeast.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: November 17, 2020
    Assignee: BAYMEDICA, INC.
    Inventors: Philip J. Barr, Charles K. Marlowe, Jianping Sun
  • Publication number: 20180334692
    Abstract: The present invention relates generally to production methods, enzymes and recombinant yeast strains for the biosynthesis of clinically important prenylated polyketides of the cannabinoid family. Using readily available starting materials, heterologous enzymes are used to direct cannabinoid biosynthesis in yeast.
    Type: Application
    Filed: May 10, 2018
    Publication date: November 22, 2018
    Inventors: Philip J. Barr, Charles K. Marlowe, Jianping Sun
  • Patent number: 10125381
    Abstract: The invention relates to the production of aromatic molecules in prokaryotic and eukaryotic hosts such as E. coli, yeasts, filamentous fungi, algae, microalgae, other plant cells.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: November 13, 2018
    Assignee: RHO RENEWABLES, INC.
    Inventor: Philip J. Barr
  • Publication number: 20170253893
    Abstract: The invention relates to the production of aromatic molecules in prokaryotic and eukaryotic hosts such as E. coli, yeasts, filamentous fungi, algae, microalgae, other plant cells.
    Type: Application
    Filed: March 23, 2017
    Publication date: September 7, 2017
    Inventor: Philip J. Barr
  • Patent number: 9637763
    Abstract: The invention relates to the production of aromatic molecules in prokaryotic and eukaryotic hosts such as E. coli, yeasts, filamentous fungi, algae, microalgae, other plant cells.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: May 2, 2017
    Assignee: RHO Renewables, Inc.
    Inventor: Philip J. Barr
  • Publication number: 20140220648
    Abstract: The invention relates to the production of aromatic molecules in prokaryotic and eukaryotic hosts such as E. coli, yeasts, filamentous fungi, algae, microalgae, other plant cells.
    Type: Application
    Filed: June 22, 2012
    Publication date: August 7, 2014
    Applicant: RHO Renewables
    Inventor: Philip J. Barr
  • Publication number: 20120142099
    Abstract: The present invention provides polynucleotide sequences (bbp) encoding a Bak Binding Protein (BBP) and fragments thereof that bind to Bak. The invention also provides a BBP which binds to Bak. The invention also provides recombinant host cells containing polynucleotides encoding BBP. The invention further provides antibodies that specifically bind to BBP. The invention further provides methods for detecting agents such as drugs that alter the binding of a BBP with a Bak protein. The invention further provides methods for detecting the presence of bbp or BBP in a biological sample, and further provides methods for modulating the levels of BBP in a cell. This invention additionally encompasses novel peptides, designated the “BBP Binding Domains” and the respective nucleotides, designated “bbpbd-1” and “bbpbd-2” which are involved in the interaction between Bak and BBP.
    Type: Application
    Filed: January 19, 2011
    Publication date: June 7, 2012
    Applicant: GENENTECH, INC.
    Inventors: Michael C. Kiefer, Paul A. Fitzpatrick, Helen L. Gibson, Philip J. Barr
  • Patent number: 7914771
    Abstract: The present invention encompasses methods and compositions for the treatment and prevention of chronic obstructive pulmonary disease (COPD) or emphysema, typically smoking-induced emphysema. More specifically, the present invention relates to the treatment and prevention of COPD or emphysema by inhalation of alpha one-antitrypsin (AAT).
    Type: Grant
    Filed: March 9, 2005
    Date of Patent: March 29, 2011
    Assignee: Arriva Pharmaceuticals, Inc.
    Inventors: Philip J. Barr, Philip A. Pemberton, Helen L. Gibson
  • Patent number: 7892825
    Abstract: Vectors, host cells, and methods are provided for the production of proteins in yeast. The vectors generally contain a selection gene, a yeast 2 micron sequence, and a polynucleotide encoding a polypeptide, where the polynucleotide is operably linked to promoter, and where the polynucleotide contains one or more yeast-preferred codons. Host cells are cultured under conditions where, after an initial batch phase, oxygen concentration is kept high and glucose feed is regulated so that the yeast cells stay in respiratory metabolism.
    Type: Grant
    Filed: July 7, 2008
    Date of Patent: February 22, 2011
    Assignee: Arriva Pharmaceuticals, Inc.
    Inventors: Philip J. Barr, Helen L. Gibson
  • Patent number: 7888038
    Abstract: The present invention provide polynucleotide sequences encoding a Bak Binding Protein (BBP) and fragments thereof that bind to Bak. The invention also provide recombinant host cells containing polynucleotides encoding BBP. The invention further provide antibodies that specifically bind to BBP. The invention further provide methods for detecting agents such as drugs that alter the binding of a BBP with a Bak protein. The invention further provide methods for detecting the presence of Bak polynucleotides and the encoding proteins in a biological sample, and further provide methods for modulating the levels of BBP in a cell. This invention additionally encompasses novel peptides, designated the “BBP Binding Domains” and the respective nucleotides, designated “bbpbd-1” and “bbpbd-2” which are involved in the interaction between Bak and BBP.
    Type: Grant
    Filed: October 9, 2006
    Date of Patent: February 15, 2011
    Assignee: Genetech, Inc.
    Inventors: Michael C. Kiefer, Paul A. Fitzpatrick, Helen L. Gibson, Philip J. Barr
  • Publication number: 20110032253
    Abstract: A miniaturized antenna system is characterized non-destructively through the use of a scanner that measures its near-field radiated power performance. When taking measurements, the scanner can be moved linearly along the x, y and z axis, as well as rotationally relative to the antenna. The data obtained from the characterization are processed to determine the far-field properties of the system and to optimize the system. Each antenna is excited using a probe station system while a scanning probe scans the space above the antenna to measure the near field signals. Upon completion of the scan, the near-field patterns are transformed into far-field patterns. Along with taking data, this system also allows for extensive graphing and analysis of both the near-field and far-field data. The details of the probe station as well as the procedures for setting up a test, conducting a test, and analyzing the resulting data are also described.
    Type: Application
    Filed: August 16, 2010
    Publication date: February 10, 2011
    Inventors: Afroz J. Zaman, Richard Q. Lee, William G. Darby, Philip J. Barr, Kevin M. Lambert, Felix A. Miranda
  • Patent number: 7876276
    Abstract: A miniaturized antenna system is characterized non-destructively through the use of a scanner that measures its near-field radiated power performance. When taking measurements, the scanner can be moved linearly along the x, y and z axis, as well as rotationally relative to the antenna. The data obtained from the characterization are processed to determine the far-field properties of the system and to optimize the system. Each antenna is excited using a probe station system while a scanning probe scans the space above the antenna to measure the near field signals. Upon completion of the scan, the near-field patterns are transformed into far-field patterns. Along with taking data, this system also allows for extensive graphing and analysis of both the near-field and far-field data. The details of the probe station as well as the procedures for setting up a test, conducting a test, and analyzing the resulting data are also described.
    Type: Grant
    Filed: August 2, 2006
    Date of Patent: January 25, 2011
    Assignee: The United States of America as represented by the Administrator of the National Aeronautics and Space Administration
    Inventors: Afroz J. Zaman, Richard Q. Lee, William G. Darby, Philip J. Barr, Kevin M Lambert, Felix A. Miranda
  • Publication number: 20100286066
    Abstract: Alpha 1-antitrypsin compositions and treatment methods using such compositions for treating a variety of pulmonary diseases are provided. The compositions generally contain AAT, a stabilizing carbohydrate such as trehalose, a surfactant such as Polysorbate 80 and an antioxidant to stabilize AAT for use as a therapeutic. The formulations can be prepared as both liquids and solids and administered by nebulization of the liquid formulation or by conversion of dry powder formulation into an aerosol.
    Type: Application
    Filed: February 26, 2010
    Publication date: November 11, 2010
    Inventors: Manzer Durrani, Harish Kumar, Timothy Krieger, Ken Kabingue, Virginia Mosher, Philip J. Barr, Ian C. Bathurst
  • Patent number: 7754418
    Abstract: The present invention provides a novel family of apoptosis-modulating proteins. Nucleotide and amino acid residue sequences and methods of use thereof are also provided.
    Type: Grant
    Filed: March 16, 2005
    Date of Patent: July 13, 2010
    Assignee: Genentech, Inc.
    Inventors: Michael C. Kiefer, Philip J. Barr
  • Patent number: 7709446
    Abstract: Fusion proteins of protease inhibitors are provided, in particular fusion proteins of alpha 1-antitrypsin (AAT) and a second protease inhibitor, such as secretory leukocyte protease inhibitor (SLPI) or tissue inhibitor of metalloproteases (TIMP). Polynucleotides encoding the fusion proteins, vectors comprising such polynucleotides, and host cells containing such vectors are also provided. Methods of making the fusion proteins of the invention are also provide, as well as methods of using the fusion proteins, for example to inhibit protease activity in a biological sample or in the treatment of an individual suffering from, or at risk for, a disease or disorder involving unwanted protease activity.
    Type: Grant
    Filed: July 20, 2007
    Date of Patent: May 4, 2010
    Assignee: Arrive Pharmaceuticals, Inc.
    Inventors: Philip J. Barr, Helen L. Gibson, Philip A. Pemberton
  • Patent number: 7527925
    Abstract: Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: May 5, 2009
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Paul A. Luciw, Dino Dina, Kathelyn Steimer, Ray Sanchez Pescador, Carlos George-Nascimento, Deborah Parkes, Rob Hallewell, Philip J. Barr, Martha Truett
  • Publication number: 20090042278
    Abstract: Vectors, host cells, and methods are provided for the production of proteins in yeast. The vectors generally contain a selection gene, a yeast 2 micron sequence, and a polynucleotide encoding a polypeptide, where the polynucleotide is operably linked to promoter, and where the polynucleotide contains one or more yeast-preferred codons. Host cells are cultured under conditions where, after an initial batch phase, oxygen concentration is kept high and glucose feed is regulated so that the yeast cells stay in respiratory metabolism.
    Type: Application
    Filed: July 7, 2008
    Publication date: February 12, 2009
    Applicant: ARRIVA PHARMACEUTICALS, INC.
    Inventors: Philip J. Barr, Helen L. Gibson
  • Publication number: 20080312136
    Abstract: Alpha 1-antitrypsin compositions and treatment methods using such compositions for treating a variety of pulmonary diseases are provided. The compositions generally contain AAT, a stabilizing carbohydrate such as trehalose, a surfactant such as Polysorbate 80 and an antioxidant to stabilize AAT for use as a therapeutic. The formulations can be prepared as both liquids and solids and administered by nebulization of the liquid formulation or by conversion of dry powder formulation into an aerosol.
    Type: Application
    Filed: November 11, 2004
    Publication date: December 18, 2008
    Inventors: Manzer Durrani, Harish Kumar, Timothy Krieger, Ken Kabingue, Virginia Mosher, Philip J. Barr, Ian C. Bathurst
  • Patent number: 7442525
    Abstract: Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: October 28, 2008
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Paul A. Luciw, Dino Dina, Kathelyn Steimer, Ray Sanchez Pescador, Carlos George-Nascimento, Deborah Parkes, Rob Hallewell, Philip J. Barr, Martha Truett
  • Patent number: 7425428
    Abstract: Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: September 16, 2008
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Paul A. Luciw, Dino Dina, Kathelyn Steimer, Ray Sanchez Pescador, Carlos George-Nascimento, Deborah Parkes, Rob Hallewell, Philip J. Barr, Martha Truett